ATOS

MKT CAP:$50M

Atossa Therapeutics, Inc.

Market Cap

$50M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$5.77-$3.69 (-39.01%)

Apr 21, 2026

Company Details

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead dr...

CEO

Steven C. Quay

IPO Date

Nov 8, 2012

Website

www.atossatherapeutics.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$35M

EPS (Diluted)

-$4.04

Free Cash Flow

-$30M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 12, 2026

PENDING

FY 2025

Mar 25, 2026

$0EPS -$4.04

Q4 2025

Mar 25, 2026

$0EPS -$1.27

Q3 2025

Nov 12, 2025

$0EPS -$1.01

Q2 2025

Aug 12, 2025

$0EPS -$0.98

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	-$2.0K	-$5M
Q2 22	$0	-$2.0K	-$7M
Q3 22	$0	-$2.0K	-$8M
Q4 22	$0	-$2.0K	-$8M
Q1 23	$0	-$3.0K	-$7M
Q2 23	$0	-$3.0K	-$8M
Q3 23	$0	-$3.0K	-$7M
Q4 23	$18.0K	-$14.0K	-$9M
Q1 24	$0	-$5.0K	-$7M
Q2 24	$0	-$4.0K	-$7M
Q3 24	$0	-$4.0K	-$6M
Q4 24	$0	-$4.0K	-$7M
Q1 25	$0	-$4.0K	-$7M
Q2 25	$0	-$4.0K	-$9M
Q3 25	$0	-$4.0K	-$9M
Q4 25	$0	-$4.0K	-$11M

Valuation

Quarter	P/S	P/E
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	99211.5x	—
Q1 24	209553.6x	—
Q2 24	125772.7x	—
Q3 24	160387.1x	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$5M	-$5M
Q2 22	-$6M	-$6M
Q3 22	-$5M	-$5M
Q4 22	-$5M	-$5M
Q1 23	-$7M	-$7M
Q2 23	-$4M	-$4M
Q3 23	-$4M	-$4M
Q4 23	-$6M	-$6M
Q1 24	-$5M	-$5M
Q2 24	-$5M	-$5M
Q3 24	-$5M	-$5M
Q4 24	-$7M	-$7M
Q1 25	-$6M	-$6M
Q2 25	-$7M	-$7M
Q3 25	-$6M	-$6M
Q4 25	-$11M	-$11M

Capital Expenditures

Quarter	CapEx
Q1 22	$13.0K
Q2 22	$0
Q3 22	$6.0K
Q4 22	$8.0K
Q1 23	$0
Q2 23	$13.0K
Q3 23	$1.0K
Q4 23	$0
Q1 24	$6.0K
Q2 24	$3.0K
Q3 24	$10.0K
Q4 24	$0
Q1 25	$9.0K
Q2 25	$0
Q3 25	$7.0K
Q4 25	$7.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+34.4%
Q2 22	—	-5.8%
Q3 22	—	+59.1%
Q4 22	—	+68.6%
Q1 23	—	+49.5%
Q2 23	—	+18.2%
Q3 23	—	-9.0%
Q4 23	—	+11.0%
Q1 24	—	-1.7%
Q2 24	—	-8.8%
Q3 24	—	-14.5%
Q4 24	-100.0%	-20.9%
Q1 25	—	+6.2%
Q2 25	—	+27.2%
Q3 25	—	+44.9%
Q4 25	—	+59.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$2M	—
Q2 22	$2M	—
Q3 22	$2M	—
Q4 22	$2M	—
Q1 23	$2M	—
Q2 23	$2M	—
Q3 23	$926.0K	—
Q4 23	$519.0K	2883.3%
Q1 24	$417.0K	—
Q2 24	$352.0K	—
Q3 24	$749.0K	—
Q4 24	$774.0K	—
Q1 25	$563.0K	—
Q2 25	$796.0K	—
Q3 25	$784.0K	—
Q4 25	$503.0K	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$1M	$3M	—
Q2 22	$3M	$3M	—
Q3 22	$5M	$3M	—
Q4 22	$4M	$3M	—
Q1 23	$4M	$4M	—
Q2 23	$4M	$4M	—
Q3 23	$4M	$3M	—
Q4 23	$6M	$3M	—
Q1 24	$4M	$3M	—
Q2 24	$4M	$4M	—
Q3 24	$3M	$3M	—
Q4 24	$3M	$4M	—
Q1 25	$4M	$3M	—
Q2 25	$6M	$4M	—
Q3 25	$5M	$4M	—
Q4 25	$6M	—	$5M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$131M	$0	$131M
Q2 22	$126M	$0	$126M
Q3 22	$117M	$0	$117M
Q4 22	$111M	$0	$111M
Q1 23	$104M	$0	$104M
Q2 23	$100M	$0	$100M
Q3 23	$94M	$0	$94M
Q4 23	$88M	$0	$88M
Q1 24	$84M	$0	$84M
Q2 24	$80M	$0	$80M
Q3 24	$75M	$0	$75M
Q4 24	$71M	$0	$71M
Q1 25	$65M	$0	$65M
Q2 25	$58M	$0	$58M
Q3 25	$52M	$0	$52M
Q4 25	$41M	$0	$41M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	8M	+0.1%	+36.8%
Q2 22	8M	0.0%	+4.2%
Q3 22	8M	0.0%	+0.1%
Q4 22	8M	0.0%	+0.1%
Q1 23	8M	0.0%	0.0%
Q2 23	8M	-0.0%	-0.0%
Q3 23	8M	-0.7%	-0.7%
Q4 23	8M	-0.4%	-1.0%
Q1 24	8M	+0.0%	-1.0%
Q2 24	8M	+0.3%	-0.7%
Q3 24	8M	+0.0%	-0.0%
Q4 24	8M	+0.7%	+1.1%
Q1 25	9M	+2.0%	+3.1%
Q2 25	9M	+0.0%	+2.7%
Q3 25	9M	+0.0%	+2.7%
Q4 25	9M	-0.0%	+2.0%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	4
Q2 22	$0	4
Q3 22	$0	4
Q4 22	$0	9
Q1 23	$0	9
Q2 23	$0	9
Q3 23	$0	9
Q4 23	$1.8K	10
Q1 24	$0	10
Q2 24	$0	10
Q3 24	$0	10
Q4 24	$0	13
Q1 25	$0	13
Q2 25	$0	13
Q3 25	$0	13
Q4 25	$0	14

Revenue / Employee